Literature DB >> 19671920

Specific iron chelators determine the route of ferritin degradation.

Ivana De Domenico1, Diane McVey Ward, Jerry Kaplan.   

Abstract

Deferoxamine (DFO) is a high-affinity Fe (III) chelator produced by Streptomyces pilosus. DFO is used clinically to remove iron from patients with iron overload disorders. Orally administered DFO cannot be absorbed, and therefore it must be injected. Here we show that DFO induces ferritin degradation in lysosomes through induction of autophagy. DFO-treated cells show cytosolic accumulation of LC3B, a critical protein involved in autophagosomal-lysosomal degradation. Treatment of cells with the oral iron chelators deferriprone and desferasirox did not show accumulation of LC3B, and degradation of ferritin occurred through the proteasome. Incubation of DFO-treated cells with 3-methyladenine, an autophagy inhibitor, resulted in degradation of ferritin by the proteasome. These results indicate that ferritin degradation occurs by 2 routes: a DFO-induced entry of ferritin into lysosomes and a cytosolic route in which iron is extracted from ferritin before degradation by the proteasome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671920      PMCID: PMC2777130          DOI: 10.1182/blood-2009-05-224188

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  Autophagy as a regulated pathway of cellular degradation.

Authors:  D J Klionsky; S D Emr
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

2.  Neisseria meningitidis accelerates ferritin degradation in host epithelial cells to yield an essential iron source.

Authors:  Jason A Larson; Heather L Howie; Magdalene So
Journal:  Mol Microbiol       Date:  2004-08       Impact factor: 3.501

Review 3.  Deferoxamine pharmacokinetics.

Authors:  J B Porter
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

4.  Ferritin oxidation in vitro: implication of iron release and degradation by the 20S proteasome.

Authors:  M Rudeck; T Volk; N Sitte; T Grune
Journal:  IUBMB Life       Date:  2000-05       Impact factor: 3.885

Review 5.  TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals.

Authors:  N S Cutler; J Heitman; M E Cardenas
Journal:  Mol Cell Endocrinol       Date:  1999-09-10       Impact factor: 4.102

Review 6.  Transition metal transport in yeast.

Authors:  Anthony Van Ho; Diane McVey Ward; Jerry Kaplan
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

7.  Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.

Authors:  J C Kwok; D R Richardson
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

8.  Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo.

Authors:  Shan Soe-Lin; Sameer S Apte; Billy Andriopoulos; Marc C Andrews; Matthias Schranzhofer; Tanya Kahawita; Daniel Garcia-Santos; Prem Ponka
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

Review 9.  Iron, ferritin, and nutrition.

Authors:  Elizabeth C Theil
Journal:  Annu Rev Nutr       Date:  2004       Impact factor: 11.848

10.  Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts.

Authors:  Eeva-Liisa Eskelinen; Christine Katrin Schmidt; Silja Neu; Marion Willenborg; Graciela Fuertes; Natalia Salvador; Yoshitaka Tanaka; Renate Lüllmann-Rauch; Dieter Hartmann; Jörg Heeren; Kurt von Figura; Erwin Knecht; Paul Saftig
Journal:  Mol Biol Cell       Date:  2004-04-30       Impact factor: 4.138

View more
  62 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Elemental economy: microbial strategies for optimizing growth in the face of nutrient limitation.

Authors:  Sabeeha S Merchant; John D Helmann
Journal:  Adv Microb Physiol       Date:  2012       Impact factor: 3.517

3.  Decoupling ferritin synthesis from free cytosolic iron results in ferritin secretion.

Authors:  Ivana De Domenico; Michael B Vaughn; Prasad N Paradkar; Eric Lo; Diane M Ward; Jerry Kaplan
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

4.  Rapid monitoring of iron-chelating therapy in thalassemia major by a new cardiovascular MR measure: the reduced transverse relaxation rate.

Authors:  Daniel Kim; Jens H Jensen; Ed X Wu; Li Feng; Wing-Yan Au; Jerry S Cheung; Shau-Yin Ha; Sujit S Sheth; Gary M Brittenham
Journal:  NMR Biomed       Date:  2010-12-28       Impact factor: 4.044

Review 5.  Cellular and mitochondrial iron homeostasis in vertebrates.

Authors:  Caiyong Chen; Barry H Paw
Journal:  Biochim Biophys Acta       Date:  2012-01-18

6.  Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Authors:  Yang-Sung Sohn; Anna-Maria Mitterstiller; William Breuer; Guenter Weiss; Z Ioav Cabantchik
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells.

Authors:  Takeshi Asano; Masaaki Komatsu; Yuko Yamaguchi-Iwai; Fuyuki Ishikawa; Noboru Mizushima; Kazuhiro Iwai
Journal:  Mol Cell Biol       Date:  2011-03-28       Impact factor: 4.272

8.  Oxidative stress increases HO-1 expression in ARPE-19 cells, but melanosomes suppress the increase when light is the stressor.

Authors:  Anna Pilat; Anja M Herrnreiter; Christine M B Skumatz; Tadeusz Sarna; Janice M Burke
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

9.  Iron increases the susceptibility of multiple myeloma cells to bortezomib.

Authors:  Alessandro Campanella; Paolo Santambrogio; Francesca Fontana; Michela Frenquelli; Simone Cenci; Magda Marcatti; Roberto Sitia; Giovanni Tonon; Clara Camaschella
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

Review 10.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.